_id
6915ea2dbc934aba376b1c49
Ticker
PYXS
Name
Pyxis Oncology Inc
Exchange
NASDAQ
Address
321 Harrison Avenue, Boston, MA, United States, 02118
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.pyxisoncology.com
Description
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Last Close
4.41
Volume
1738366
Current Price
4.3
Change
-2.4943310657596443
Last Updated
2025-12-03T12:35:13.998Z
Image
data:image/webp;base64,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
Ipo Date
2021-10-08T00:00:00.000Z
Market Cap
243453088
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.991
Sentiment Sources
1
Rating
4.4286
Target Price
7.675
Strong Buy
4
Buy
2
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
0
Gross Profit
0
Operating Expenses
23461000
Operating Income
-23461000
Interest Expense
-
Pretax Income
-22003000
Net Income
-22003000
Eps
-0.35172505449636277
Dividends Per Share
-
Shares Outstanding
62264215
Income Tax Expense
-
EBITDA
-21468000
Operating Margin
-
Total Other Income Expense Net
1458000
Cash
10391000
Short Term Investments
67337000
Receivables
-
Inventories
-
Total Current Assets
83073000
Property Plant Equipment
20097000
Total Assets
105604000
Payables
9756000
Short Term Debt
1630000
Long Term Debt
-
Total Liabilities
36825000
Equity
68779000
Depreciation
527000
Change In Working Capital
5448000
Cash From Operations
-13277000
Capital Expenditures
9000
Cash From Investing
11471000
Cash From Financing
-8000
Net Change In Cash
-1814000
PE
-
PB
4.011080013666962
ROE
-31.990869306038178
ROA
-20.835385023294574
FCF
-13286000
Fcf Percent
-
Piotroski FScore
1
Health Score
34
Deep Value Investing Score
2.5
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2
Growth Investing Score
1
Momentum Investing Score
3.5
Net Net Investing Score
2.5
Quality Investing Score
2
Value Investing Score
3
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
0
Quarters > 0 > income Statement > gross Profit
0
Quarters > 0 > income Statement > operating Expenses
23461000
Quarters > 0 > income Statement > operating Income
-23461000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-22003000
Quarters > 0 > income Statement > net Income
-22003000
Quarters > 0 > income Statement > eps
-0.35172505449636277
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
62557386
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-21468000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
1458000
Quarters > 0 > balance Sheet > cash
10391000
Quarters > 0 > balance Sheet > short Term Investments
67337000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
83073000
Quarters > 0 > balance Sheet > property Plant Equipment
20097000
Quarters > 0 > balance Sheet > total Assets
105604000
Quarters > 0 > balance Sheet > payables
9756000
Quarters > 0 > balance Sheet > short Term Debt
1630000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
36825000
Quarters > 0 > balance Sheet > equity
68779000
Quarters > 0 > cash Flow > net Income
-22003000
Quarters > 0 > cash Flow > depreciation
527000
Quarters > 0 > cash Flow > change In Working Capital
5448000
Quarters > 0 > cash Flow > cash From Operations
-13277000
Quarters > 0 > cash Flow > capital Expenditures
9000
Quarters > 0 > cash Flow > cash From Investing
11471000
Quarters > 0 > cash Flow > cash From Financing
-8000
Quarters > 0 > cash Flow > net Change In Cash
-1814000
Quarters > 0 > ratios > PE
-0.35172505449636277
Quarters > 0 > ratios > PB
4.011080013666962
Quarters > 0 > ratios > ROE
-31.990869306038178
Quarters > 0 > ratios > ROA
-20.835385023294574
Quarters > 0 > ratios > FCF
-13286000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
34
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
2820000
Quarters > 1 > income Statement > cost Of Revenue
535000
Quarters > 1 > income Statement > gross Profit
2820000
Quarters > 1 > income Statement > operating Expenses
22570000
Quarters > 1 > income Statement > operating Income
-19750000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-18071000
Quarters > 1 > income Statement > net Income
-18354000
Quarters > 1 > income Statement > eps
-0.29642034879666485
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
61918826
Quarters > 1 > income Statement > income Tax Expense
283000
Quarters > 1 > income Statement > EBITDA
-19215000
Quarters > 1 > income Statement > operating Margin
-700.354609929078
Quarters > 1 > income Statement > total Other Income Expense Net
1679000
Quarters > 1 > balance Sheet > cash
10733000
Quarters > 1 > balance Sheet > short Term Investments
78211000
Quarters > 1 > balance Sheet > receivables
3000000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
99956000
Quarters > 1 > balance Sheet > property Plant Equipment
20771000
Quarters > 1 > balance Sheet > total Assets
123215000
Quarters > 1 > balance Sheet > payables
9412000
Quarters > 1 > balance Sheet > short Term Debt
1568000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
35572000
Quarters > 1 > balance Sheet > equity
87643000
Quarters > 1 > cash Flow > net Income
-18354000
Quarters > 1 > cash Flow > depreciation
535000
Quarters > 1 > cash Flow > change In Working Capital
-1765000
Quarters > 1 > cash Flow > cash From Operations
-17263000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
15304000
Quarters > 1 > cash Flow > cash From Financing
-67000
Quarters > 1 > cash Flow > net Change In Cash
-2026000
Quarters > 1 > ratios > PE
-0.29642034879666485
Quarters > 1 > ratios > PB
3.1156170220097446
Quarters > 1 > ratios > ROE
-20.941775156030715
Quarters > 1 > ratios > ROA
-14.895913646877409
Quarters > 1 > ratios > FCF
-17263000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-6.121631205673759
Quarters > 1 > health Score
30
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
552000
Quarters > 2 > income Statement > gross Profit
-552000
Quarters > 2 > income Statement > operating Expenses
22914000
Quarters > 2 > income Statement > operating Income
-22914000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-21158000
Quarters > 2 > income Statement > net Income
-21158000
Quarters > 2 > income Statement > eps
-0.34657435866052927
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
61048948
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-22362000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
1756000
Quarters > 2 > balance Sheet > cash
12759000
Quarters > 2 > balance Sheet > short Term Investments
92673000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
111871000
Quarters > 2 > balance Sheet > property Plant Equipment
21452000
Quarters > 2 > balance Sheet > total Assets
135867000
Quarters > 2 > balance Sheet > payables
2846000
Quarters > 2 > balance Sheet > short Term Debt
1508000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
32764000
Quarters > 2 > balance Sheet > equity
103103000
Quarters > 2 > cash Flow > net Income
-21158000
Quarters > 2 > cash Flow > depreciation
552000
Quarters > 2 > cash Flow > change In Working Capital
-4596000
Quarters > 2 > cash Flow > cash From Operations
-22535000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
15821000
Quarters > 2 > cash Flow > cash From Financing
0
Quarters > 2 > cash Flow > net Change In Cash
-6714000
Quarters > 2 > ratios > PE
-0.34657435866052927
Quarters > 2 > ratios > PB
2.6112320754973184
Quarters > 2 > ratios > ROE
-20.521226346469064
Quarters > 2 > ratios > ROA
-15.572582010348354
Quarters > 2 > ratios > FCF
-22535000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
42
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
3402000
Quarters > 3 > income Statement > cost Of Revenue
1701000
Quarters > 3 > income Statement > gross Profit
1701000
Quarters > 3 > income Statement > operating Expenses
40069000
Quarters > 3 > income Statement > operating Income
-40069000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-37735000
Quarters > 3 > income Statement > net Income
-35571000
Quarters > 3 > income Statement > eps
-0.5858680059196534
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
60715041
Quarters > 3 > income Statement > income Tax Expense
-2164000
Quarters > 3 > income Statement > EBITDA
-18555000
Quarters > 3 > income Statement > operating Margin
-1177.8071722516167
Quarters > 3 > income Statement > total Other Income Expense Net
2334000
Quarters > 3 > balance Sheet > cash
19473000
Quarters > 3 > balance Sheet > short Term Investments
107458000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
132440000
Quarters > 3 > balance Sheet > property Plant Equipment
22141000
Quarters > 3 > balance Sheet > total Assets
157181000
Quarters > 3 > balance Sheet > payables
4859000
Quarters > 3 > balance Sheet > short Term Debt
1450000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
36430000
Quarters > 3 > balance Sheet > equity
120751000
Quarters > 3 > cash Flow > net Income
-35571000
Quarters > 3 > cash Flow > depreciation
550000
Quarters > 3 > cash Flow > change In Working Capital
-6659000
Quarters > 3 > cash Flow > cash From Operations
-19290000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
26657000
Quarters > 3 > cash Flow > cash From Financing
50000
Quarters > 3 > cash Flow > net Change In Cash
7417000
Quarters > 3 > ratios > PE
-0.5858680059196534
Quarters > 3 > ratios > PB
2.217400525130227
Quarters > 3 > ratios > ROE
-29.458141133406762
Quarters > 3 > ratios > ROA
-22.63059784579561
Quarters > 3 > ratios > FCF
-19290000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-5.670194003527337
Quarters > 3 > health Score
35
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
16146000
Annuals > 0 > income Statement > cost Of Revenue
475000
Annuals > 0 > income Statement > gross Profit
15671000
Annuals > 0 > income Statement > operating Expenses
105131000
Annuals > 0 > income Statement > operating Income
-89460000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-79495000
Annuals > 0 > income Statement > net Income
-77331000
Annuals > 0 > income Statement > eps
-1.3231240963310174
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
58445765
Annuals > 0 > income Statement > income Tax Expense
-2164000
Annuals > 0 > income Statement > EBITDA
-65514000
Annuals > 0 > income Statement > operating Margin
-554.0691192865106
Annuals > 0 > income Statement > total Other Income Expense Net
9965000
Annuals > 0 > balance Sheet > cash
19473000
Annuals > 0 > balance Sheet > short Term Investments
107458000
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
132440000
Annuals > 0 > balance Sheet > property Plant Equipment
22141000
Annuals > 0 > balance Sheet > total Assets
157181000
Annuals > 0 > balance Sheet > payables
4859000
Annuals > 0 > balance Sheet > short Term Debt
1450000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
36430000
Annuals > 0 > balance Sheet > equity
120751000
Annuals > 0 > cash Flow > net Income
-77331000
Annuals > 0 > cash Flow > depreciation
2982000
Annuals > 0 > cash Flow > change In Working Capital
-11823000
Annuals > 0 > cash Flow > cash From Operations
-57672000
Annuals > 0 > cash Flow > capital Expenditures
237000
Annuals > 0 > cash Flow > cash From Investing
8155000
Annuals > 0 > cash Flow > cash From Financing
59326000
Annuals > 0 > cash Flow > net Change In Cash
9809000
Annuals > 0 > ratios > PE
-1.3231240963310174
Annuals > 0 > ratios > PB
1.8925138603407015
Annuals > 0 > ratios > ROE
-64.0417056587523
Annuals > 0 > ratios > ROA
-49.198694498698956
Annuals > 0 > ratios > FCF
-57909000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-3.5865849126718694
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
2000000
Annuals > 1 > income Statement > gross Profit
-2000000
Annuals > 1 > income Statement > operating Expenses
82196000
Annuals > 1 > income Statement > operating Income
-82196000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-73790000
Annuals > 1 > income Statement > net Income
-73790000
Annuals > 1 > income Statement > eps
-1.8491601081709796
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
39904603
Annuals > 1 > income Statement > income Tax Expense
1776000
Annuals > 1 > income Statement > EBITDA
-80269000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
8406000
Annuals > 1 > balance Sheet > cash
9664000
Annuals > 1 > balance Sheet > short Term Investments
109634000
Annuals > 1 > balance Sheet > receivables
21000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
124604000
Annuals > 1 > balance Sheet > property Plant Equipment
24814000
Annuals > 1 > balance Sheet > total Assets
173726000
Annuals > 1 > balance Sheet > payables
3896000
Annuals > 1 > balance Sheet > short Term Debt
1232000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
48022000
Annuals > 1 > balance Sheet > equity
125704000
Annuals > 1 > cash Flow > net Income
-73790000
Annuals > 1 > cash Flow > depreciation
1927000
Annuals > 1 > cash Flow > change In Working Capital
-11664000
Annuals > 1 > cash Flow > cash From Operations
-70709000
Annuals > 1 > cash Flow > capital Expenditures
6726000
Annuals > 1 > cash Flow > cash From Investing
-104849000
Annuals > 1 > cash Flow > cash From Financing
5929000
Annuals > 1 > cash Flow > net Change In Cash
-169629000
Annuals > 1 > ratios > PE
-1.8491601081709796
Annuals > 1 > ratios > PB
1.2412254003850316
Annuals > 1 > ratios > ROE
-58.701393750397756
Annuals > 1 > ratios > ROA
-42.47493178913922
Annuals > 1 > ratios > FCF
-77435000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
34
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
1836000
Annuals > 2 > income Statement > gross Profit
-1836000
Annuals > 2 > income Statement > operating Expenses
123481000
Annuals > 2 > income Statement > operating Income
-123481000
Annuals > 2 > income Statement > interest Expense
2764000
Annuals > 2 > income Statement > pretax Income
-120717000
Annuals > 2 > income Statement > net Income
-117953000
Annuals > 2 > income Statement > eps
-3.5707538149408466
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
33033081
Annuals > 2 > income Statement > income Tax Expense
-2764000
Annuals > 2 > income Statement > EBITDA
-122772000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
2764000
Annuals > 2 > balance Sheet > cash
179293000
Annuals > 2 > balance Sheet > short Term Investments
0
Annuals > 2 > balance Sheet > receivables
598000
Annuals > 2 > balance Sheet > inventories
874000
Annuals > 2 > balance Sheet > total Current Assets
186612000
Annuals > 2 > balance Sheet > property Plant Equipment
24767000
Annuals > 2 > balance Sheet > total Assets
211379000
Annuals > 2 > balance Sheet > payables
7097000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
50555000
Annuals > 2 > balance Sheet > equity
160824000
Annuals > 2 > cash Flow > net Income
-120717000
Annuals > 2 > cash Flow > depreciation
709000
Annuals > 2 > cash Flow > change In Working Capital
4501000
Annuals > 2 > cash Flow > cash From Operations
-89335000
Annuals > 2 > cash Flow > capital Expenditures
6399000
Annuals > 2 > cash Flow > cash From Investing
-6399000
Annuals > 2 > cash Flow > cash From Financing
183000
Annuals > 2 > cash Flow > net Change In Cash
-95551000
Annuals > 2 > ratios > PE
-3.5707538149408466
Annuals > 2 > ratios > PB
0.8031099009476198
Annuals > 2 > ratios > ROE
-73.34290901855445
Annuals > 2 > ratios > ROA
-55.80166430913194
Annuals > 2 > ratios > FCF
-95734000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
34
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
1251000
Annuals > 3 > income Statement > gross Profit
-1251000
Annuals > 3 > income Statement > operating Expenses
69717000
Annuals > 3 > income Statement > operating Income
-69717000
Annuals > 3 > income Statement > interest Expense
6258000
Annuals > 3 > income Statement > pretax Income
-75975000
Annuals > 3 > income Statement > net Income
-75975000
Annuals > 3 > income Statement > eps
-2.3577966228407696
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
32222881
Annuals > 3 > income Statement > income Tax Expense
5561000
Annuals > 3 > income Statement > EBITDA
-69070000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-6258000
Annuals > 3 > balance Sheet > cash
274735000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
278673000
Annuals > 3 > balance Sheet > property Plant Equipment
1239000
Annuals > 3 > balance Sheet > total Assets
280021000
Annuals > 3 > balance Sheet > payables
11951000
Annuals > 3 > balance Sheet > short Term Debt
165000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
18708000
Annuals > 3 > balance Sheet > equity
261313000
Annuals > 3 > cash Flow > net Income
-75975000
Annuals > 3 > cash Flow > depreciation
647000
Annuals > 3 > cash Flow > change In Working Capital
6676000
Annuals > 3 > cash Flow > cash From Operations
-35326000
Annuals > 3 > cash Flow > capital Expenditures
540000
Annuals > 3 > cash Flow > cash From Investing
-590000
Annuals > 3 > cash Flow > cash From Financing
304044000
Annuals > 3 > cash Flow > net Change In Cash
268128000
Annuals > 3 > ratios > PE
-2.3577966228407696
Annuals > 3 > ratios > PB
0.48214771063820017
Annuals > 3 > ratios > ROE
-29.074328487293016
Annuals > 3 > ratios > ROA
-27.13189367940262
Annuals > 3 > ratios > FCF
-35866000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
33
Valuation > metrics > PE
-0.35172505449636277
Valuation > metrics > PB
4.011080013666962
Valuation > final Score
39.889199863330376
Valuation > verdict
33.7% Overvalued
Profitability > metrics > ROE
-31.990869306038178
Profitability > metrics > ROA
-26.486343336583484
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.535410517745242
Risk > metrics > Interest Coverage
-43.85233644859813
Risk > final Score
-127
Risk > verdict
High
Liquidity > metrics > Current Ratio
7.29606534340418
Liquidity > metrics > Quick Ratio
7.29606534340418
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
48.843829779902556
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
-9
Prev Risks > 1
-16
Prev Risks > 2
52
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-12T21:19:40.216Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-25
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
-0.3213
Earnings History > 0 > eps Difference
0.3213
Earnings History > 0 > surprise Percent
100
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-03
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.35
Earnings History > 1 > eps Estimate
-0.34
Earnings History > 1 > eps Difference
-0.01
Earnings History > 1 > surprise Percent
-2.9412
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-14
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.3
Earnings History > 2 > eps Estimate
-0.34
Earnings History > 2 > eps Difference
0.04
Earnings History > 2 > surprise Percent
11.7647
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-06-11
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
-0.35
Earnings History > 3 > eps Estimate
-0.24
Earnings History > 3 > eps Difference
-0.11
Earnings History > 3 > surprise Percent
-45.8333
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-03-19
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-1.32
Earnings History > 4 > eps Estimate
-0.32
Earnings History > 4 > eps Difference
-1
Earnings History > 4 > surprise Percent
-312.5
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-12
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.35
Earnings History > 5 > eps Estimate
-0.32
Earnings History > 5 > eps Difference
-0.03
Earnings History > 5 > surprise Percent
-9.375
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-11
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.29
Earnings History > 6 > eps Estimate
-0.32
Earnings History > 6 > eps Difference
0.03
Earnings History > 6 > surprise Percent
9.375
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-14
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.06
Earnings History > 7 > eps Estimate
-0.24
Earnings History > 7 > eps Difference
0.18
Earnings History > 7 > surprise Percent
75
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-03-21
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.33
Earnings History > 8 > eps Estimate
-0.47
Earnings History > 8 > eps Difference
0.14
Earnings History > 8 > surprise Percent
29.7872
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-11-07
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-0.56
Earnings History > 9 > eps Estimate
-0.51
Earnings History > 9 > eps Difference
-0.05
Earnings History > 9 > surprise Percent
-9.8039
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-08-11
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
BeforeMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-0.41
Earnings History > 10 > eps Estimate
-0.65
Earnings History > 10 > eps Difference
0.24
Earnings History > 10 > surprise Percent
36.9231
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-05-11
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
BeforeMarket
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-0.55
Earnings History > 11 > eps Estimate
-0.9
Earnings History > 11 > eps Difference
0.35
Earnings History > 11 > surprise Percent
38.8889
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-03-22
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
BeforeMarket
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-1.01
Earnings History > 12 > eps Estimate
-0.93
Earnings History > 12 > eps Difference
-0.08
Earnings History > 12 > surprise Percent
-8.6022
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-11-01
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
BeforeMarket
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
-0.85
Earnings History > 13 > eps Estimate
-0.81
Earnings History > 13 > eps Difference
-0.04
Earnings History > 13 > surprise Percent
-4.9383
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-08-15
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
BeforeMarket
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
-0.79
Earnings History > 14 > eps Estimate
-0.76
Earnings History > 14 > eps Difference
-0.03
Earnings History > 14 > surprise Percent
-3.9474
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-05-13
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
BeforeMarket
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
-0.97
Earnings History > 15 > eps Estimate
-0.61
Earnings History > 15 > eps Difference
-0.36
Earnings History > 15 > surprise Percent
-59.0164
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2022-03-29
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
BeforeMarket
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
-1.98
Earnings History > 16 > eps Estimate
-0.37
Earnings History > 16 > eps Difference
-1.61
Earnings History > 16 > surprise Percent
-435.1351
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-11-15
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
BeforeMarket
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
-8.96
Earnings History > 17 > eps Estimate
-0.51
Earnings History > 17 > eps Difference
-8.45
Earnings History > 17 > surprise Percent
-1656.8627
Earnings History > 18 > period
2021-06-30
Earnings History > 18 > report Date
2021-09-01
Earnings History > 18 > date
2021-06-30
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
-1.02
Earnings History > 18 > eps Estimate
0
Earnings History > 18 > eps Difference
-1.02
Earnings History > 18 > surprise Percent
-
Earnings History > 19 > period
2021-03-31
Earnings History > 19 > report Date
2021-06-30
Earnings History > 19 > date
2021-03-31
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
-15.9309
Earnings History > 19 > eps Estimate
0
Earnings History > 19 > eps Difference
-15.9309
Earnings History > 19 > surprise Percent
-
Earnings History > 20 > period
2020-12-31
Earnings History > 20 > report Date
2021-03-31
Earnings History > 20 > date
2020-12-31
Earnings History > 20 > before After Market
-
Earnings History > 20 > currency
USD
Earnings History > 20 > eps Actual
-15.9309
Earnings History > 20 > eps Estimate
0
Earnings History > 20 > eps Difference
-15.9309
Earnings History > 20 > surprise Percent
-
Earnings History > 21 > period
2020-03-31
Earnings History > 21 > report Date
2020-06-30
Earnings History > 21 > date
2020-03-31
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
USD
Earnings History > 21 > eps Actual
-2.7373
Earnings History > 21 > eps Estimate
0
Earnings History > 21 > eps Difference
-2.7373
Earnings History > 21 > surprise Percent
-
Earnings History > 22 > period
2019-12-31
Earnings History > 22 > report Date
2020-03-31
Earnings History > 22 > date
2019-12-31
Earnings History > 22 > before After Market
-
Earnings History > 22 > currency
USD
Earnings History > 22 > eps Actual
-2.7373
Earnings History > 22 > eps Estimate
0
Earnings History > 22 > eps Difference
-2.7373
Earnings History > 22 > surprise Percent
-
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AShowing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$7.675
Analyst Picks
Strong Buy
4
Buy
2
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 46.64% of the total shares of Pyxis Oncology Inc
1.
Pfizer Inc(11.3399%)
since
2025/06/30
2.
LAURION CAPITAL MANAGEMENT LP(5.8466%)
since
2025/06/30
3.
Millennium Management LLC(5.7078%)
since
2025/06/30
4.
TANG CAPITAL MANAGEMENT LLC(4.0311%)
since
2025/06/30
5.
Vanguard Group Inc(3.4658%)
since
2025/06/30
6.
Vanguard Total Stock Mkt Idx Inv(2.0429%)
since
2025/07/31
7.
Palo Alto Investors, LLC(1.6728%)
since
2025/06/30
8.
BlackRock Inc(1.4944%)
since
2025/06/30
9.
Aberdeen Group PLC(1.4722%)
since
2025/06/30
10.
683 Capital Management LLC(0.8788%)
since
2025/06/30
11.
Vanguard Institutional Extnd Mkt Idx Tr(0.8672%)
since
2025/07/31
12.
Geode Capital Management, LLC(0.8239%)
since
2025/06/30
13.
Renaissance Technologies Corp(0.6737%)
since
2025/06/30
14.
UBS Group AG(0.6387%)
since
2025/06/30
15.
PIER 88 INVESTMENT PARTNERS LLC(0.592%)
since
2025/06/30
16.
Jane Street Group LLC(0.5419%)
since
2025/06/30
17.
Decheng Capital LLC(0.527%)
since
2025/06/30
18.
Schulhoff & CO Inc(0.4434%)
since
2025/06/30
19.
iShares Biotechnology ETF(0.4386%)
since
2025/08/31
20.
Fidelity Extended Market Index(0.3978%)
since
2025/07/31
21.
Goldman Sachs Group Inc(0.3616%)
since
2025/06/30
22.
State Street Corp(0.3%)
since
2025/06/30
23.
Bank of New York Mellon Corp(0.2661%)
since
2025/06/30
24.
Morgan Stanley - Brokerage Accounts(0.2583%)
since
2025/06/30
25.
Bridgeway Ultra-Small Company Market(0.2049%)
since
2025/06/30
26.
iShares Micro-Cap ETF(0.172%)
since
2025/08/31
27.
Extended Equity Market Fund K(0.1682%)
since
2025/06/30
28.
Fidelity Total Market Index(0.1331%)
since
2025/07/31
29.
Fidelity Series Total Market Index(0.1025%)
since
2025/07/31
30.
Spartan Extended Market Index Pool F(0.095%)
since
2025/07/31
31.
NT Ext Equity Mkt Idx Fd - L(0.0919%)
since
2025/06/30
32.
Northern Trust Extended Eq Market Idx(0.0919%)
since
2025/06/30
33.
NT Col R2000 Val Idx Fd -DC -L -TierFour(0.0881%)
since
2025/03/31
34.
HBM Healthcare Investments AG Ord(0.0826%)
since
2025/06/30
35.
NT Ext Equity Mkt Idx Fd - NL(0.0678%)
since
2025/06/30
36.
NT Ext Equity Mkt Idx Fd - DC - NL - T2(0.0526%)
since
2025/06/30
37.
Vanguard Instl Ttl Stck Mkt Idx Tr(0.0518%)
since
2024/12/31
38.
Vanguard Instl Ttl Stk Mkt Idx InstlPls(0.0518%)
since
2025/07/31
39.
iShares Nasdaq US Biotech ETF USD Acc(0.0507%)
since
2025/08/31
40.
Fidelity Nasdaq Composite Index(0.0486%)
since
2025/07/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.3213
Date
2025-09-30
EPS Actual
-0.35
EPS Estimate
-0.34
EPS Difference
-0.01
Surprise Percent
-2.9412%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.